Needham & Company Downgrades Optimer Pharmaceuticals (OPTR) to Hold on Weaker Dificid Sales; Says Takeover Hopes Dim
Tweet Send to a Friend
Needham & Company downgraded Optimer Pharmaceuticals (NASDAQ: OPTR) from Buy to Hold following Q1 results which included weak Deficid sales.
This article: 268 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 268 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
